143 related articles for article (PubMed ID: 17162129)
61. [Clinical significance of expression of VEGF and bFGF in thyroid carcinoma].
Tian XF; Zhang XW; Chen RX; Wang JW; Zhang D
Zhonghua Wai Ke Za Zhi; 2004 Jul; 42(14):864-6. PubMed ID: 15363277
[TBL] [Abstract][Full Text] [Related]
62. The expression of monocyte chemotactic protein-1 in papillary thyroid carcinoma is correlated with lymph node metastasis and tumor recurrence.
Tanaka K; Kurebayashi J; Sohda M; Nomura T; Prabhakar U; Yan L; Sonoo H
Thyroid; 2009 Jan; 19(1):21-5. PubMed ID: 19072670
[TBL] [Abstract][Full Text] [Related]
63. Lateral cervical lymph node metastases from papillary thyroid carcinoma: pattern of nodal metastases and optimal strategy for neck dissection.
Roh JL; Kim JM; Park CI
Ann Surg Oncol; 2008 Apr; 15(4):1177-82. PubMed ID: 18253801
[TBL] [Abstract][Full Text] [Related]
64. Predictive factors of level IIb lymph node metastasis in patients with papillary thyroid carcinoma.
Koo BS; Yoon YH; Kim JM; Choi EC; Lim YC
Ann Surg Oncol; 2009 May; 16(5):1344-7. PubMed ID: 19224280
[TBL] [Abstract][Full Text] [Related]
65. Decreased expression of p27 is associated with malignant transformation and extrathyroidal extension in papillary thyroid carcinoma.
Do SI; Kim DH; Yang JH; Pyo JS; Kim K; Lee H; Do IG; Kim DH; Chae SW; Sohn JH
Tumour Biol; 2016 Mar; 37(3):3359-64. PubMed ID: 26446458
[TBL] [Abstract][Full Text] [Related]
66. Comparative topoisomerase IIa and ki 67 protein expression in papillary thyroid carcinoma based on tissue microarrays and image analysis.
Manaios L; Tsiambas E; Alevizaki M; Karameris A; Alexopoulou D; Lambropoulou S; Moreas H; Kravvaritis C; Fotiades PP; Goula K; Patsouris E; Athanassiou AE; Koutras D; Katsilambros N
J BUON; 2008; 13(4):537-41. PubMed ID: 19145676
[TBL] [Abstract][Full Text] [Related]
67. Central neck dissection for papillary thyroid cancer.
Rosenbaum MA; McHenry CR
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1092-7. PubMed ID: 19917920
[TBL] [Abstract][Full Text] [Related]
68. Sentinel lymph node biopsy as guidance for central neck dissection in patients with papillary thyroid carcinoma.
Roh JL; Park CI
Cancer; 2008 Oct; 113(7):1527-31. PubMed ID: 18671238
[TBL] [Abstract][Full Text] [Related]
69. Diffuse (or multinodular) follicular variant of papillary thyroid carcinoma: a clinicopathologic and immunohistochemical analysis of ten cases of an aggressive form of differentiated thyroid carcinoma.
Ivanova R; Soares P; Castro P; Sobrinho-Simões M
Virchows Arch; 2002 Apr; 440(4):418-24. PubMed ID: 11956824
[TBL] [Abstract][Full Text] [Related]
70. Patterns of cyclin E, retinoblastoma protein, and p21Cip1/WAF1 immunostaining in the oncogenesis of papillary thyroid carcinoma.
Brzeziński J; Migodziński A; Toczek A; Tazbir J; Dedecjus M
Clin Cancer Res; 2005 Feb; 11(3):1037-43. PubMed ID: 15709169
[TBL] [Abstract][Full Text] [Related]
71. The expression of sialic fibronectin correlates with lymph node metastasis of thyroid malignant neoplasmas.
Takeyama H; Kyoda S; Okamoto T; Manome Y; Watanabe M; Kinoshita S; Uchida K; Sakamoto A; Morikawa T
Anticancer Res; 2011 Apr; 31(4):1395-8. PubMed ID: 21508391
[TBL] [Abstract][Full Text] [Related]
72. [Usefulness of the immunohistochemical analysis of several molecular markers in the characterization of papillary thyroid carcinoma with initial lymph node metastasis].
Zafón C; Castellví J; Obiols G
Endocrinol Nutr; 2010 Apr; 57(4):165-9. PubMed ID: 20403734
[TBL] [Abstract][Full Text] [Related]
73. Correlation between proliferating cell nuclear antigen and p53 protein expression and 5-year survival rate in nasopharyngeal carcinoma.
Wang LF; Chai CY; Kuo WR; Tai CF; Lee KW; Ho KY
Am J Otolaryngol; 2006; 27(2):101-5. PubMed ID: 16500472
[TBL] [Abstract][Full Text] [Related]
74. Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma.
Freudenberg LS; Sheu S; Görges R; Mann K; Bokler S; Frilling A; Schmid KW; Bockisch A; Otterbach F
Nuklearmedizin; 2005; 44(5):179-82, 184. PubMed ID: 16395492
[TBL] [Abstract][Full Text] [Related]
75. Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid.
Nasir A; Catalano E; Calafati S; Cantor A; Kaiser HE; Coppola D
In Vivo; 2004; 18(2):189-95. PubMed ID: 15113046
[TBL] [Abstract][Full Text] [Related]
76. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications.
Jarzab B; Wiench M; Fujarewicz K; Simek K; Jarzab M; Oczko-Wojciechowska M; Wloch J; Czarniecka A; Chmielik E; Lange D; Pawlaczek A; Szpak S; Gubala E; Swierniak A
Cancer Res; 2005 Feb; 65(4):1587-97. PubMed ID: 15735049
[TBL] [Abstract][Full Text] [Related]
77. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
78. Correlation between calcification and bone sialoprotein and osteopontin in papillary thyroid carcinoma.
Wu G; Guo JJ; Ma ZY; Wang J; Zhou ZW; Wang Y
Int J Clin Exp Pathol; 2015; 8(2):2010-7. PubMed ID: 25973097
[TBL] [Abstract][Full Text] [Related]
79. Prognostic value of oncoprotein expressions in thyroid papillary carcinoma.
Balta AZ; Filiz AI; Kurt Y; Sucullu I; Yucel E; Akin ML
Med Oncol; 2012 Jun; 29(2):734-41. PubMed ID: 21547408
[TBL] [Abstract][Full Text] [Related]
80. Nitric oxide in papillary thyroid carcinoma: induction of vascular endothelial growth factor D and correlation with lymph node metastasis.
Nakamura Y; Yasuoka H; Zuo H; Takamura Y; Miyauchi A; Nakamura M; Kakudo K
J Clin Endocrinol Metab; 2006 Apr; 91(4):1582-5. PubMed ID: 16418215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
